AWM
PTLA

Aevitas Wealth Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Aevitas Wealth Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100
Closed -$4K – 458
2018
Q2 		$4K Hold
100
– – ﹤0.01% 382
2018
Q1 		$3K Hold
100
– – ﹤0.01% 398
2017
Q4 		$5K Buy
+100
New +$5.06K ﹤0.01% 371

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aevitas Wealth Management's PTLA Position: Q3 2018 in Review

Aevitas Wealth Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2018, closing a stake of 100 shares — an estimated $4K sold.

Aevitas Wealth Management first reported a position in PTLA in Q4 2017 and held it in 3 quarters. The position peaked at $5K in Q4 2017. 197 funds tracked by Wall St. Rank hold PTLA as of Q3 2018.

  • Aevitas Wealth Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Aevitas Wealth Management sold 100 Portola Pharmaceuticals, Inc. shares in Q3 2018, an estimated $4K.
  • Aevitas Wealth Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
  • Aevitas Wealth Management's Portola Pharmaceuticals, Inc. position peaked at $5K in Q4 2017.
  • 197 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2018.

Based on Aevitas Wealth Management's 13F filing for Q3 2018, filed 14 Nov 2018.